Loading
Every dated change on the records linked to Spinal cord tumours (intramedullary and intradural), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Belzutifan, the HIF-2 alpha inhibitor approved for VHL-associated central nervous system haemangioblastomas, with surveillance imaging.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.